The US Food and Drug Administration (FDA) has approved the Omnilink Elite Vascular Balloon-Expandable Stent System (Abbott) for the treatment of iliac arterial disease. The FDA approval is supported by positive clinical data from the MOBILITY (Omnilink Elite or Absolute Pro Stent used in the iliac artery) study. The MOBILITY study demonstrated that Omnilink Elite is safe and effective even in difficult-to-treat patients with severely calcified lesions.
On 8 August, the UK’s National Institute of Health and Clinical Excellence (NICE) published a clinical guideline on the diagnosis and management of lower limb peripheral arterial disease.
Madrid, agosto de 2012.- Sanitas Hospitales abre una nueva unidad para el tratamiento específico del pie diabético, un trastorno que afecta a los pies en forma de heridas y úlceras, y que es muy común en los pacientes con diabetes. Esta unidad implementará programas de prevención, ya que un correcto control de la diabetes es capaz de prevenir, retrasar y disminuir su aparición. La nueva unidad se encuentra ubicada en un entorno multidisciplinar que involucra a varias especialidades, y que engloba al Hospital Sanitas la Zarzuela, Sanitas la Moraleja, el Centro Médico Milenium Conde Duque y el Centro Médico Milenium Reina Victoria.
Phosphate binders can lower serum phosphorus levels for patients with chronic kidney disease (CKD), but they may also increase vascular calcification, researchers found.
Novel Platform Based Technology Combines Multiple Functions in Single Device. Acquisition includes Portfolio of FDA 510(k) Cleared Catheters for Dialysis Access and Peripheral Angioplasty
Agreement targets vein practices in U.S., 20 other countries Patented, head-mounted vascular imaging device offers practitioners the first truly hands-free, portable system for locating veins A powerful tool for performing sclerotherapy and phlebectomy
Angioslide, a provider of embolic capture angioplasty solutions, has announced the successful deployment of a 3X100mm Proteus device for treating peripheral artery disease in below-the-knee (BTK) vasculature at Community Hospital in Munster, USA. Accommodating a 0.014” guide-wire, the new device allows physician to perform a PTA revascularisation in BTK vessels while capturing and removing embolic particles.
Reprocessing of popular vein treatment catheter results in significant cost savings and medical waste reduction for vein practices Nearly 300 clinics have contracted to have their ClosureFAST catheters reprocessed since launch of the service on January 16, 2012
Terumo Interventional Systems, a strategic business unit of Terumo Medical Corporation, a U.S. subsidiary of Terumo Corporation, today announced the completion of U.S. patient enrollment in the Occlusive/Stenotic Peripheral Artery REvascularization StudY (OSPREY) designed to evaluate the safety and effectiveness of the MISAGOT Self-expanding Stent System. OSPREY is a single-arm, multi-center, non-randomized prospective clinical trial for the treatment of atherosclerotic stenoses and occlusions of the superficial femoral artery that included 200 patients in 31 centers in the U.S. and 100 patients in seven centers in Japan.
La Federación Española de Asociaciones de Linfedema (FEDEAL), entidad miembro de COCEMFE, participó en el Congreso que celebró la International Lynphedema Framework en la ciudad francesa de Montpellier los pasados días 27 al 30 de Junio. Durante su ponencia, FEDEAL presentó la situación en nuestro país, a través de un manifiesto que asegura que existen afectados de Linfedema en todas las Comunidades Autónomas que no están diagnosticados o lo son de forma tardía, muchos no reciben una información correcta sobre la enfermedad, hay largas listas de espera o problemas para acceder a un tratamiento intensivo que incluya el necesario mantenimiento, y muchos pacientes se ven forzados a costearse su propia atención médica.
The use of fenestrated stent grafts has been approved by the U.S. Food and Drug Administration (FDA). Vascular surgeons at the Washington University and Barnes-Jewish Heart & Vascular Center are one of few in the country to offer this treatment option for abdominal aortic aneurysm patients.
AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, announced that it has received a Notice of Allowance for its patent application for Dissolution of Arterial Plaque. The patent will issue within the next few months when the US Patent Office completes its registration process. This announcement culminates over five years of effort in pursuit of a patent covering the use of hyodeoxycholic acid for atherosclerotic plaque lesions.
Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) has assigned a priority review designation to the supplemental New Drug Applications (sNDAs) filed on May 2, 2012 for XARELTO® (rivaroxaban), an oral anticoagulant, seeking new indications to treat patients with deep vein thrombosis (DVT), pulmonary embolism (PE), and to prevent recurrent DVT and PE.
The US Food and Drug Administration (FDA) has given clearance to r4 Vascular to market its Vector Percutaneous Transluminal Angioplasty (PTA) balloon catheters in 28 sizes. All Vector balloon catheter sizes are rated for up to 30 atmospheres of pressure and are radiopaque when deflated or inflated.
The medium term results of a first-in-man structured registry have shown that Spiral Flow Grafts enhance treatment for patients with peripheral artery disease. The study is due to be published in the October issue of the Annals of Vascular Surgery.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos